Ovarian cancer immunotherapy: non-standard solution — non-standard respons
https://doi.org/10.62546/3034-1477-2023-1-1-49-55
Abstract
Ovarian cancer is a serious problem in clinical oncology due to the frequent detection of the disease in late stages, as well as the extremely low effectiveness of treatment at the stage of development of resistance to platinum drugs. The use of immunotherapy in this setting is not a standard option, but several early phase trials of its potential effectiveness are described in the literature. This clinical case presents a successful experience with the use of immune checkpoint inhibitors in a pretreated patient with platinum-resistant metastatic ovarian cancer, which was accompanied by various immune-related adverse events.
About the Authors
M. I. Gluzman
St. Petersburg State University; City Clinical Oncology Dispensary
Russian Federation
Russian Federation
Gluzman Mark Igorevich — candidate of medical sciences, associate professor of the department of oncology; head of the chemotherapy department (antitumor drug therapy) No. 12
AuthorID 853558
St. Petersburg
N. V. Tyukavina
City Hospital No. 40
Russian Federation
Russian Federation
Tyukavina Nina Vladimirovna — head of the department of antitumor drug therapy
AuthorID 700523
St. Petersburg
D. S. Rudenko
City Hospital No. 40
Russian Federation
Russian Federation
Rudenko Daria Sergeevna — oncologist
St. Petersburg
R. V. Orlova
St. Petersburg State University; City Clinical Oncology Dispensary
Russian Federation
Russian Federation
Orlova Rashida Vakhidovna — Doctor of Medical Sciences, Prof., Head. Department of Oncology; Ch. clinical oncology specialist
Author ID 401170
St. Petersburg
References
1. Bowtell D.D., Böhm S., Ahmed A.A. et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer // Nat. Rev. Cancer. 2015. Vol. 15. Р. 668–679. doi: 10.1038/nrc4019.
2. Cannistra S.A. Cancer of the ovary // N. Engl. J. Med. 2004. Vol. 351. Р. 2519–2529. doi: 10.1056/NEJMra041842.
3. Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA Cancer. J. Clin. 2021. Vol. 71. Р. 209–249. doi: 10.3322/caac.21660.
4. Ledermann J., Harter P., Gourley C. et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial // Lancet Oncol. 2014. Vol. 15. Р. 852–861. doi: 10.1016/S1470-2045(14)70228-1.
5. Ahmed A.A., Etemadmoghadam D., Temple J. et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary // J. Pathol. 2010. Vol. 221. Р. 49–56. doi: 10.1002/path.2696.
6. Lheureux S., Gourley C., Vergote I. et al. Epithelial ovarian cancer // Lancet. 2019. Vol. 393. Р. 1240–1253. doi: 10.1016/S0140-6736(18)32552-2.
7. Armstrong D.K., Alvarez R.D., Bakkum-Gamez J.N. et al. Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology // J. Natl. Compr. Canc. Netw. 2021. Vol. 19. Р. 191–226. doi: 10.6004/jnccn.2021.0007.
8. Siminiak N., Czepczyński R., Zaborowski M.P., Iżycki D. Immunotherapy in Ovarian Cancer // Arch. Immunol. Ther. Exp. (Warsz). 2022. Aug. 9; Vol. 70, No. 1. Р. 19. doi: 10.1007/s00005-022-00655-8.
9. Katsumata N., Yasuda M., Isonishi S. et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial // Lancet Oncol. 2013. Vol. 14. Р. 1020–1026. doi: 10.1016/S1470-2045(13)70363-2.
10. Wright A.A., Bohlke K., Armstrong D.K. et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline // J. Gynecol. Oncol. 2016. Vol. 34. Р. 3460–3473.
11. Poveda A.M., Selle F., Hilpert F. et al. Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: Analysis by chemotherapy cohort of the randomized Phase III AURELIA trial // J. Clin. Oncol. 2015. Vol. 3. Р. 3836–3838. doi: 10.1200/JCO.2015.63.1408.
12. González-Martín A., Pothuri B., Vergote I. et al. Niraparib in patients with newly diagnosed advanced ovarian cancer // N. Engl. J. Med. 2019. Vol. 381. Р. 2391–2402. doi: 10.1056/NEJMoa1910962.
13. Moore K., Colombo N., Scambia G. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer // N. Engl. J. Med. 2018. Vol. 379. Р. 2495–2505. doi: 10.1056/NEJMoa1810858.
14. Ray-Coquard I., Pautier P., Pignata S. et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer // N. Engl. J. Med. 2019. Vol. 381. Р. 2416–2428. doi: 10.1056/NEJMoa1911361.
15. Matulonis U.A. Ovarian cancer // Hematol. Oncol. Clin. N. Am. 2018. Vol. 32, No. 6. Р. XIII–XIV. doi: 10.1016/j.hoc.2018.09.006.
16. Levinson K., Dorigo O., Rubin K. et al. Immunotherapy in gynecologic cancers: what we know now and where we are headed // Am. Soc. Clin. Oncol. Educ. Book. 2019. Vol. 39. e126–e140. doi: 10.1200/EDBK_237967.
17. Lynam S., Lugade A.A., Odunsi K. Immunotherapy for gynecologic cancer: current applications and future directions // Clin. Obstetrics Gynecol. 2020. Vol. 63. Р. 48–63. doi: 10.1097/GRF.0000000000000513.
18. Brahmer J.R., Tykodi S.S., Chow L.Q.M. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancers // N. Engl. J. Med. 2012. Vol. 366, No. 26. Р. 2455–2465. doi: 10.1056/NEJMoa1200694.
19. Awada A., Ahmad S., McKenzie N.D., Holloway R.W. Immunotherapy in the Treatment of Platinum-Resistant Ovarian Cancer: Current Perspectives // Onco Targets Ther. 2022. Vol. 10, No. 15. Р. 853–866. doi: 10.2147/OTT.S335936.
20. Matulonis U.A., Shapira-Frommer R., Santin A.D. et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study // Ann. Oncol. 2019. Vol. 30, No. 7. Р. 1080–1087. doi: 10.1093/annonc/mdz135
21. Zamarin D., Burger R.A., Sill M.W. et al. Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study // J. Clin. Oncol. 2020. Vol. 38, No. 16. Р. 1814–1823. doi: 10.1200/JCO.19.02059.
22. Wang L. Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study // J. Ovarian. Res. 2019. Vol. 12. Р. 37. doi: 10.1186/s13048-019-0512-6.
23. Pawłowska A., Kwiatkowska A., Suszczyk D. et al. Clinical and prognostic value of antigen-presenting cells with PD- L1/PD-L2 expression in ovarian cancer patients // Int. J. Mol. Sci. 2021. Vol. 22. Р. 11563. doi: 10.3390/ijms222111563.
24. Oaknin A., Tinker A.V., Gilbert L. et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair–deficient endometrial cancer: a nonrandomized Phase 1 clinical trial // JAMA Oncol. 2020. Vol. 6. Р. 1766–1772. doi: 10.1001/jamaoncol.2020.4515.
25. Bonneville R., Krook M.A., Kautto E.A. et al. Landscape of microsatellite instability across 39 cancer types // CO Precis Oncol. 2017. Vol. 2017. PO.17.00073. doi: 10.1200/PO.17.00073.
26. Ledermann J.A., Raja F.A., Fotopoulou C., Gonzalez-Martin A., Colombo N., Sessa C.; ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann. Oncol. 2013. Vol. 24, Suppl. 6. vi24–32. doi: 10.1093/annonc/mdt333.
Review
For citations:
Gluzman M.I., Tyukavina N.V., Rudenko D.S., Orlova R.V. Ovarian cancer immunotherapy: non-standard solution — non-standard respons. Clinical Case in Oncology. 2023;1(1):49-55. (In Russ.) https://doi.org/10.62546/3034-1477-2023-1-1-49-55
Views:
290
Email this article 